| Year |
Citation |
Score |
| 2019 |
Chen C, Hartzema AG, Xiao H, Wei YJ, Chaudhry N, Ewelukwa O, Glover SC, Zimmermann EM. Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy. Inflammatory Bowel Diseases. PMID 30839057 DOI: 10.1093/Ibd/Izz001 |
0.337 |
|
| 2018 |
Kim J, Hartzema AG. Decline in dopamine agonists prescribing and characteristics of drugs prescribed during ambulatory office visits for restless legs syndrome: the National Ambulatory Medical Care Survey 2007-2015. Sleep Medicine. 54: 238-243. PMID 30590306 DOI: 10.1016/J.Sleep.2018.11.011 |
0.338 |
|
| 2015 |
Xu Y, Zhou X, Suehs BT, Hartzema AG, Kahn MG, Moride Y, Sauer BC, Liu Q, Moll K, Pasquale MK, Nair VP, Bate A. A Comparative Assessment of Observational Medical Outcomes Partnership and Mini-Sentinel Common Data Models and Analytics: Implications for Active Drug Safety Surveillance. Drug Safety. 38: 749-65. PMID 26055920 DOI: 10.1007/S40264-015-0297-5 |
0.308 |
|
| 2015 |
Ali AK, Hartzema AG, Winterstein AG, Segal R, Lu X, Hendeles L. Application of multicategory exposure marginal structural models to investigate the association between long-acting beta-agonists and prescribing of oral corticosteroids for asthma exacerbations in the Clinical Practice Research Datalink. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 18: 260-70. PMID 25773561 DOI: 10.1016/J.Jval.2014.11.007 |
0.635 |
|
| 2014 |
Boyce RD, Ryan PB, Norén GN, Schuemie MJ, Reich C, Duke J, Tatonetti NP, Trifirò G, Harpaz R, Overhage JM, Hartzema AG, Khayter M, Voss EA, Lambert CG, Huser V, et al. Bridging islands of information to establish an integrated knowledge base of drugs and health outcomes of interest. Drug Safety. 37: 557-67. PMID 24985530 DOI: 10.1007/S40264-014-0189-0 |
0.307 |
|
| 2014 |
Rivera DR, Hartzema AG. Pediatric Exclusivity: Evolving Legislation and Novel Complexities within Pediatric Therapeutic Development Annals of Pharmacotherapy. 48: 369-379. PMID 24311725 DOI: 10.1177/1060028013514031 |
0.335 |
|
| 2014 |
Ali AK, Winterstein A, Hendeles L, Lu X, Segal R, Hartzema A. Comparison Of Rates Of Prescribing Oral Corticosteroids For Asthma Exacerbations Between Step-Down Therapy Approaches Among Initiators Of Inhaled Corticosteroids and Long-Acting Beta-Agonist Combination Therapy Journal of Allergy and Clinical Immunology. 133: AB177. DOI: 10.1016/J.Jaci.2013.12.635 |
0.636 |
|
| 2013 |
Ryan PB, Schuemie MJ, Welebob E, Duke J, Valentine S, Hartzema AG. Defining a reference set to support methodological research in drug safety. Drug Safety. 36: S33-47. PMID 24166222 DOI: 10.1007/S40264-013-0097-8 |
0.304 |
|
| 2013 |
Madigan D, Ryan PB, Schuemie M, Stang PE, Overhage JM, Hartzema AG, Suchard MA, DuMouchel W, Berlin JA. Evaluating the impact of database heterogeneity on observational study results. American Journal of Epidemiology. 178: 645-51. PMID 23648805 DOI: 10.1093/Aje/Kwt010 |
0.324 |
|
| 2013 |
Ali A, Hartzema A. Prescribing Long-Acting Beta-Agonists As Monotherapy To Adults With Controlled And Uncontrolled Asthma Value in Health. 16: A241. DOI: 10.1016/J.Jval.2013.03.1225 |
0.636 |
|
| 2013 |
Ali A, Hartzema A, Hendeles L, Lu X, Winterstein A, Segal R. Long-Acting Beta-Agonists And Asthma Exacerbations Requiring Short Courses Of Oral Corticosteroids: A Multi-Category Exposure Marginal Structural Models Analysis Value in Health. 16: A231. DOI: 10.1016/J.Jval.2013.03.1173 |
0.635 |
|
| 2012 |
Ali AK, Hartzema AG. Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting. Journal of Asthma and Allergy. 5: 1-9. PMID 22690127 DOI: 10.2147/Jaa.S29811 |
0.632 |
|
| 2011 |
Hartzema AG, Racoosin JA, MaCurdy TE, Gibbs JM, Kelman JA. Utilizing Medicare claims data for real‐time drug safety evaluations:is it feasible? Pharmacoepidemiology and Drug Safety. 20: 684-8. PMID 21847800 DOI: 10.1002/Pds.2143 |
0.304 |
|
| 2010 |
Stang PE, Ryan PB, Racoosin JA, Overhage JM, Hartzema AG, Reich C, Welebob E, Scarnecchia T, Woodcock J. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Annals of Internal Medicine. 153: 600-6. PMID 21041580 DOI: 10.7326/0003-4819-153-9-201011020-00010 |
0.325 |
|
| 2010 |
Ryan P, Welebob E, Hartzema AG, Stang P, Overhage JM. Surveying US Observational Data Sources and Characteristics for Drug Safety Needs Pharmaceutical Medicine. 24: 231-238. DOI: 10.1007/Bf03256821 |
0.32 |
|
| 2009 |
Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. American Journal of Hematology. 84: 323-7. PMID 19358302 DOI: 10.1002/Ajh.21408 |
0.314 |
|
| 2009 |
LaVista JM, Treise DM, Dunbar LN, Ritho J, Hartzema AG, Lottenberg R. Development and evaluation of a patient empowerment video to promote hydroxyurea adoption in sickle cell disease. Journal of the National Medical Association. 101: 251-7. PMID 19331257 DOI: 10.1016/S0027-9684(15)30853-1 |
0.358 |
|
| 2007 |
Hartzema AG, Kauf TL, Coates TD, Huazhi L, Mody-Patel N. Economic Burden of Sickle Cell Disease among Children and Adults. Blood. 110: 958-958. DOI: 10.1182/Blood.V110.11.958.958 |
0.337 |
|
| 2007 |
Ritho JN, Mayhew DY, Hartzema AG, Liu H, Lottenberg R. Hydroxyurea Use in Sickle Cell Disease Patients in a Florida Medicaid Population. Blood. 110: 79-79. DOI: 10.1182/Blood.V110.11.79.79 |
0.661 |
|
| 2006 |
Winterstein AG, Hartzema AG, Johns TE, De Leon JM, McDonald K, Henshaw Z, Pannell R. Medication safety infrastructure in critical-access hospitals in Florida American Journal of Health-System Pharmacy. 63: 442-450. PMID 16484518 DOI: 10.2146/Ajhp050345 |
0.332 |
|
| 2006 |
Dunbar L, Coleman L, Hartzema AG, Deleon JM, Lottenberg R. Transfusion (Tx) Practices in the Management of Sickle Cell Disease (SCD) among Florida Physicians. Blood. 108: 3342-3342. DOI: 10.1182/Blood.V108.11.3342.3342 |
0.31 |
|
| 2005 |
Winterstein AG, Hartzema AG. Pharmacy-specific quality indicators for asthma therapy Research in Social and Administrative Pharmacy. 1: 430-445. PMID 17138488 DOI: 10.1016/J.Sapharm.2005.07.001 |
0.393 |
|
| 1999 |
Huang X, Hartzema AG, Raasch RH, Kauf TL, Norwood GJ. Economic assessment of three antimicrobial therapies for uncomplicated urinary tract infection in women. Clinical Therapeutics. 21: 1578-88. PMID 10509852 DOI: 10.1016/S0149-2918(00)80012-0 |
0.347 |
|
| 1999 |
Pradel FG, Hartzema AG, Mutran EJ, Hanson-Divers C. Physician over-the-counter drug prescribing patterns: An analysis of the National Ambulatory Medical Care Survey Annals of Pharmacotherapy. 33: 400-405. PMID 10332528 DOI: 10.1345/Aph.18247 |
0.342 |
|
| 1997 |
West SL, Savitz DA, Koch G, Sheff KL, Strom BL, Guess HA, Hartzema AG. Demographics, health behaviors, and past drug use as predictors of recall accuracy for previous prescription medication use. Journal of Clinical Epidemiology. 50: 975-80. PMID 9291884 DOI: 10.1016/S0895-4356(97)00026-7 |
0.344 |
|
| 1995 |
West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A. Recall accuracy for prescription medications: self-report compared with database information. American Journal of Epidemiology. 142: 1103-12. PMID 7485055 DOI: 10.1093/Oxfordjournals.Aje.A117563 |
0.319 |
|
| 1992 |
Stang PE, Fox JL, Hartzema AG, Porta MS, Tilson HH. Adverse drug events and the freedom of information act: An apple in eden Annals of Pharmacotherapy. 26: 238-243. PMID 1554939 DOI: 10.1177/106002809202600220 |
0.315 |
|
| 1992 |
Grabenstein JD, Schroeder DL, Bjornson DC, Hartzema AG. Pharmacoepidemiology and Military Medical Automation: Opportunity for Excellence Military Medicine. 157: 302-307. DOI: 10.1093/Milmed/157.6.302 |
0.352 |
|
| 1988 |
Serradell J, Bjornson DC, Hartzema AG. Drug utilization study methodologies: national and international perspectives. Drug Intelligence & Clinical Pharmacy. 21: 994-1001. PMID 3428169 DOI: 10.1177/106002808702101216 |
0.314 |
|
| 1987 |
Porta MS, Hartzema AG. The contribution of epidemiology to the study of drugs. Drug Intelligence & Clinical Pharmacy. 21: 741-7. PMID 3308393 DOI: 10.1177/106002808702100916 |
0.3 |
|
| 1984 |
Hartzema AG, Christensen DB. Nonmedical factors associated with the prescribing volume among family practitioners in an HMO. Medical Care. 21: 990-1000. PMID 6656329 DOI: 10.1097/00005650-198310000-00005 |
0.33 |
|
| Show low-probability matches. |